Valuation : Axonics, Inc.

Market Cap 3.63B 3.13B 2.96B 2.68B 5.03B 347B 5.06B 35.13B 13.51B 176B 13.62B 13.32B 557B P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 3.31B 2.85B 2.7B 2.45B 4.59B 316B 4.62B 32.06B 12.33B 161B 12.43B 12.16B 508B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2013-09-30
Director of Finance/CFO 41 2023-10-01
Chief Operating Officer 47 2018-07-31
Director TitleAgeSince
Director/Board Member 69 2018-01-31
Director/Board Member 74 2019-04-07
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.10% - - 3.63B
+2.06%-9.10%-29.12%-8.06% 106B
-1.66%-5.22%-29.15%-5.53% 11.47B
-1.84%-5.76%+91.21%+120.15% 9.86B
-1.34%-6.25%-56.39%-72.36% 3.94B
-2.84%-6.11%-30.69%+24.92% 2.33B
+7.16%+15.73%-11.84%-67.34% 2.11B
+1.47%-5.12% - - 1.84B
-2.10%-4.52%-24.89%-31.67% 1.5B
Average +0.10%-3.01%-12.98%-5.70% 17.34B
Weighted average by Cap. +1.29%-7.89%-20.96%-1.07%

Financials

2022 2023
Net sales 274M 236M 223M 202M 380M 26.15B 382M 2.65B 1.02B 13.29B 1.03B 1.01B 42.03B 366M 316M 299M 271M 508M 35B 511M 3.55B 1.36B 17.79B 1.38B 1.35B 56.26B
Net income -59.7M -51.48M -48.72M -44.16M -82.8M -5.7B -83.28M -578M -222M -2.9B -224M -219M -9.17B -6.09M -5.25M -4.97M -4.5M -8.44M -582M -8.49M -58.96M -22.67M -296M -22.86M -22.36M -935M
Net Debt -348M -300M -284M -258M -483M -33.26B -486M -3.37B -1.3B -16.9B -1.31B -1.28B -53.45B -317M -274M -259M -235M -440M -30.32B -443M -3.07B -1.18B -15.41B -1.19B -1.17B -48.73B
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!